Option 1: CJC-1295 Solo (EUR 109)
CJC-1295 alone is the right choice for researchers who prioritise total GH exposure and IGF-1 elevation:
Strengths: - Sustained GH elevation provides the highest total 24-hour GH exposure of any single peptide - Strong, consistent IGF-1 elevation -- valuable for body composition and recovery research - Well-characterised pharmacokinetics with extensive published data - Single-peptide simplicity reduces protocol complexity
Limitations: - Sustained (non-pulsatile) GH release does not mimic natural physiology - May elevate cortisol and prolactin at higher doses - Water retention reported in some research subjects - Receptor desensitisation may occur faster without pulsatile stimulation
Best For: Body composition research. IGF-1-focused studies. Researchers who want maximum GH exposure from a single compound. Protocols where hormonal selectivity is less critical than total GH output.
ORYN CJC-1295 Pen: 5 mg, 30-day supply, >99% purity, GMP manufactured, COA included.
Option 2: Ipamorelin Solo (EUR 109)
Ipamorelin alone is the right choice for researchers who prioritise selectivity and clean GH data:
Strengths: - Most selective GH secretagogue available -- GH only, minimal cortisol/prolactin effects - Pulsatile release mimics natural circadian GH secretion patterns - Excellent tolerability profile with minimal reported side effects - Does not significantly affect appetite (unlike other ghrelin mimetics) - Slower receptor desensitisation compared to less selective compounds
Limitations: - Lower total 24-hour GH exposure compared to sustained-release compounds - Less dramatic IGF-1 elevation - Pulsatile nature means GH is not constantly elevated -- may be insufficient for aggressive protocols
Best For: First-time GH peptide research. Studies requiring GH-isolated data without confounding hormonal changes. Sleep and recovery research (pulsatile GH aligns with nocturnal patterns). Researchers who prioritise tolerability above all else.
ORYN Ipamorelin Pen: 6 mg, 30-day supply, >99% purity, GMP manufactured, COA included.
Option 3: CJC-1295 + Ipamorelin Stack (EUR 218)
The combination is the right choice for researchers who want maximum GH output with optimised physiology:
Why It Works: CJC-1295 (GHRH pathway) and Ipamorelin (ghrelin pathway) activate different receptors. There is no competition -- each amplifies the other. The result is synergistic GH release that exceeds the mathematical sum of both peptides used alone.
Quantified Advantage: - 2-3x greater total GH release vs either peptide solo - Pulsatile peaks (Ipamorelin) on an elevated baseline (CJC-1295) -- the best of both patterns - Ipamorelin's selectivity partially offsets CJC-1295's cortisol/prolactin effects - Combined protocol produces higher IGF-1 than CJC-1295 alone
Protocol: - Administer both simultaneously, typically before bed - Standard duration: 8-12 weeks - No cycling between peptides needed -- concurrent daily use throughout
Cost-Benefit: At EUR 218 for two 30-day pens, the combination costs twice as much as either solo option but delivers 2-3x the GH output -- a favourable ratio. This is ORYN's most popular GH research stack.
Best For: Serious GH research. Body composition studies. Anti-aging and recovery protocols. Researchers who have the budget for dual peptides and want the most effective GH protocol available.
Decision Framework: Which Option to Choose
Use this framework to select the right approach for your research:
Budget: EUR 109 -- choose one peptide - CJC-1295 if total GH exposure and IGF-1 are the priority - Ipamorelin if selectivity, tolerability, and clean GH data are the priority
Budget: EUR 218 -- the combination stack - Almost always the recommended option if budget allows - 2-3x GH output for 2x the cost = positive return on investment - Covers both sustained and pulsatile GH release patterns - The most popular and well-studied GH protocol in the ORYN range
Research Phase Considerations: - Phase 1 (dose-finding): Ipamorelin solo -- cleanest data, fewest confounders - Phase 2 (efficacy): CJC-1295 + Ipamorelin stack -- maximum GH for endpoint measurement - Phase 3 (maintenance): Either solo option for long-term, lower-intensity protocols
Progression Path: Many researchers start with Ipamorelin solo to establish baseline GH response, then add CJC-1295 to quantify the synergistic benefit. This phased approach provides comparative data while building towards the optimal stack.
